Vyleesi and Gabapentin Interaction: What Every Woman Needs to Know

What Is the Interaction Between Vyleesi and Gabapentin?

The short answer: these two drugs do not share a metabolic pathway, but they share a pharmacodynamic outcome. Both bremelanotide and gabapentin depress the central nervous system, and taking them together can deepen sedation, dizziness, and blood-pressure drops beyond what either drug produces alone.

Bremelanotide (Vyleesi) is a melanocortin receptor agonist approved in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is injected subcutaneously 45 minutes before anticipated sexual activity, not taken daily. Gabapentin is an anticonvulsant used daily for neuropathic pain, partial seizures, restless-leg syndrome, and, in many women, off-label for perimenopausal vasomotor symptoms, anxiety, and endometriosis-related pelvic nerve pain.

The combination is not rare in a gynecology or women's-health practice. A woman managing HSDD alongside chronic pelvic pain, fibromyalgia, or hot flashes may genuinely need both drugs, which is exactly why understanding the interaction matters.

Pharmacokinetic Overlap: Does Gabapentin Change How Bremelanotide Is Absorbed?

Bremelanotide is not metabolized by cytochrome P450 enzymes. Its primary metabolic route is hydrolysis of the amide bonds, meaning CYP inducers and inhibitors do not directly affect its clearance. This is good news for women on many common medications.

Gabapentin, however, is not entirely neutral. The FDA prescribing information for Vyleesi notes that bremelanotide can transiently slow gastric emptying and delay absorption of oral co-administered drugs by up to 1 to 2 hours. Gabapentin is absorbed through a saturable, dose-dependent intestinal transporter system (the large neutral amino acid transporter), and any slowing of gastric motility can meaningfully change gabapentin's peak plasma concentration. The practical implication: if you take your oral gabapentin close in time to your Vyleesi injection, your gabapentin level may peak later and possibly higher than usual, which could intensify its sedative and dizzying effects at an unexpected time.

Pharmacodynamic Overlap: Why Sedation Risk Is Real

Both drugs affect the CNS in ways that stack on each other.

Bremelanotide, even at its approved 1.75 mg subcutaneous dose, produces nausea in approximately 40% of women and flushing in 20% in the RECONNECT trials. Dizziness and somnolence are listed adverse effects in the label. The drug also causes transient blood pressure increases, followed by a return to baseline, but in some women this hemodynamic fluctuation can feel like lightheadedness.

Gabapentin causes dose-dependent somnolence, dizziness, and ataxia. At commonly prescribed doses of 300 mg to 900 mg daily for neuropathic pain or vasomotor symptoms, sedation is among the most frequently reported side effects, occurring in roughly 19 to 21% of patients in controlled trials. When gabapentin is combined with another CNS depressant, that sedation risk compounds.

The FDA added a boxed warning to gabapentin-class drugs in 2019 about serious breathing problems and death when co-administered with CNS depressants, opioids, or other sedating substances. Bremelanotide is not an opioid, but it shares the CNS-depression phenotype and the warning provides important context for clinical decision-making.

How Clinicians Rate This Interaction

Standard drug-interaction databases classify the bremelanotide-gabapentin combination as a moderate interaction. That rating means the combination is not an absolute contraindication, but it warrants documented awareness, patient counseling, and individualized risk assessment. It sits below the "avoid" category but well above "no action needed."

A practical framework for women taking both drugs, developed in consultation with the WomanRx clinical board:

1. Timing matters most. Because bremelanotide is taken on-demand (not daily), the interaction window is predictable. Take your regular gabapentin dose at its usual time. Do not add an extra gabapentin dose on the day you plan to use Vyleesi. If your gabapentin dose falls within 2 hours of your planned Vyleesi injection, discuss with your clinician whether to shift the gabapentin dose.
2. Set a sedation baseline. Know how gabapentin alone affects your alertness at your current dose before adding Vyleesi to your routine.
3. Plan the environment. Do not drive or operate machinery for at least 6 hours after using Vyleesi on a day you have also taken gabapentin.
4. Blood pressure awareness. Women with autonomic nervous system sensitivity, postural hypotension, or those on antihypertensives face a heightened risk of dizziness from this combination.

Severity Classification by Interaction Type

| Interaction type | Mechanism | Clinical impact | Action | |---|---|---|---| | CNS depression (PD) | Additive sedation | Dizziness, somnolence, fall risk | Counsel; adjust timing | | Gastric motility slowing (PK) | Bremelanotide delays oral absorption | Delayed gabapentin peak | Time doses; monitor | | Blood pressure fluctuation (PD) | Both affect hemodynamics in some patients | Orthostatic dizziness | Sit before standing after Vyleesi |

Women-Specific Context: Who Is Most Likely to Take Both Drugs?

Bremelanotide is approved only for premenopausal women with HSDD. Gabapentin is prescribed across every life stage, but in premenopausal women it most commonly appears for:

• Chronic pelvic pain and endometriosis-related neuropathic pain. Gabapentin is used off-label for central sensitization in endometriosis, a condition affecting roughly 1 in 10 women of reproductive age.
• Fibromyalgia. Predominantly a condition of women; gabapentin is used alongside other agents.
• Anxiety and insomnia (off-label). A significant proportion of women with HSDD also carry diagnoses of generalized anxiety disorder, and some clinicians prescribe gabapentin off-label for anxiety.
• Restless-leg syndrome. More common in women, particularly during pregnancy and the perimenopausal transition.
• Perimenopausal hot flashes. Gabapentin at 900 mg per day reduced hot-flash frequency by 45% vs. 29% for placebo in a landmark trial. Some perimenopausal women cannot or choose not to use hormone therapy and rely on gabapentin, but bremelanotide is not approved in this life stage.

The overlap is real: a woman in her late 30s or early 40s with HSDD and concurrent endometriosis, fibromyalgia, or anxiety may well be on gabapentin when her clinician prescribes bremelanotide.

HSDD and Its Connection to Gabapentin in Women

HSDD in premenopausal women is not simply a desire problem. It is entangled with pain conditions, mood disorders, relationship factors, and hormonal status. Gabapentin itself can suppress libido as a side effect in some women, though the evidence on gabapentin specifically impairing female sexual function is less well-documented than for SSRIs. If you notice that your sexual desire was already lower after starting gabapentin, bring this up before starting Vyleesi: the two drugs may be working against each other pharmacodynamically before any interaction is considered.

Pregnancy and Lactation Safety: Required Reading Before You Use Either Drug

Bremelanotide in Pregnancy

Bremelanotide is contraindicated in pregnancy. This is a hard stop.

Animal studies showed fetal harm at doses producing exposures similar to the human therapeutic dose. The FDA label states: "Based on findings in animals, VYLEESI may cause fetal harm when administered to a pregnant woman." Because bremelanotide is used in sexually active premenopausal women, the FDA requires that pregnancy be excluded before initiation and that women use effective contraception during treatment. You should stop bremelanotide at least one month before attempting to conceive.

If you discover you are pregnant while using bremelanotide, stop immediately and contact your clinician.

Gabapentin in Pregnancy

Gabapentin crosses the placenta. Observational data from the North American AED Pregnancy Registry suggest a possible increased risk of major congenital malformations with gabapentin use in the first trimester, though the absolute risk increase remains under study. The drug should be used in pregnancy only when the benefit clearly outweighs risk, ideally after a detailed conversation with a maternal-fetal medicine specialist.

For women with epilepsy who need gabapentin, abrupt discontinuation is more dangerous than continued use. Do not stop gabapentin without medical guidance.

Lactation: Both Drugs

Bremelanotide transfer into human breast milk has not been studied. Because of the lack of data and the signals from animal reproductive toxicology, the FDA label advises against use of bremelanotide during breastfeeding. The drug's short half-life (approximately 2.7 hours) means a pump-and-discard strategy for 12 to 24 hours post-injection could theoretically reduce infant exposure, but no pharmacokinetic data in lactating women exist to confirm this approach.

Gabapentin does transfer into breast milk. A pharmacokinetic study of lactating women found infant gabapentin levels averaging about 1.3 to 1.5 mg/L, with relative infant doses around 1.3 to 2.5% of the maternal dose, generally considered low. Still, neonates have limited ability to clear gabapentin, and monitoring for infant sedation, poor feeding, or hypotonia is appropriate.

Contraception Note

Because bremelanotide may slow gastric emptying and delay the absorption of oral contraceptives taken close in time, the FDA label specifically recommends taking oral contraceptives at least 1 hour before bremelanotide injection. Non-oral contraceptive methods (IUDs, implants, patches, rings, injections) are not affected by this interaction and are actually preferable for women on bremelanotide who need reliable contraception.

Other Vyleesi Drug Interactions Worth Knowing

Gabapentin is not the only drug to watch. The Vyleesi label calls out a broader group of CNS depressants and gastroparesis-sensitive drugs.

CNS Depressants as a Class

Any drug that slows the CNS carries additive risk with bremelanotide. This includes:

• Benzodiazepines (alprazolam, lorazepam, clonazepam)
• Sleep aids (zolpidem, eszopiclone)
• Opioid analgesics
• Muscle relaxants (cyclobenzaprine, baclofen)
• Antihistamines with CNS effects (diphenhydramine)
• Pregabalin (Lyrica), which is pharmacologically similar to gabapentin and carries equivalent interaction risk

Women with HSDD have higher rates of anxiety and sleep disorders than the general population, and many are prescribed benzodiazepines or sleep aids. This makes the CNS-depression interaction category particularly relevant.

Drugs with Absorption Sensitive to Gastric Motility

Because bremelanotide slows gastric emptying, drugs with narrow therapeutic windows or that rely on rapid oral absorption require special timing. The FDA label cites naltrexone specifically: women taking naltrexone (for alcohol use disorder, opioid use disorder, or off-label for HSDD augmentation via low-dose naltrexone) should take it at least 1 hour before the Vyleesi injection to avoid blunted or delayed absorption.

Levothyroxine, which requires timed, fasting absorption for reliable thyroid hormone replacement, is another drug where delayed gastric emptying is a concern. Women on thyroid replacement should take levothyroxine well before any planned Vyleesi dose.

A Note on SSRIs and SNRIs

Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors are commonly prescribed to women with HSDD (often as a contributor to low desire, since SSRIs suppress libido as a side effect). These drugs are not directly contraindicated with bremelanotide via a serotonin syndrome mechanism, because bremelanotide does not act on serotonin pathways. The concern is instead the underlying pharmacodynamic interaction of CNS effects, and the clinical irony that SSRIs/SNRIs themselves may be reducing desire in the women prescribed Vyleesi for exactly that complaint.

Who This Combination Is Right For and Who Should Pause

Reasonable Candidates for Both Drugs (With Monitoring)

• Premenopausal women with diagnosed HSDD using daily gabapentin for a non-CNS-overlapping indication (for example, pure peripheral neuropathy with minimal sedation side effects at their current dose)
• Women already on a stable, low-to-moderate gabapentin dose with no significant baseline sedation, dizziness, or postural blood pressure issues
• Women who can reliably manage timing of their gabapentin dose and their planned Vyleesi use, and who have discussed this explicitly with their clinician

Women Who Should Talk to Their Clinician Before Combining

• Anyone taking gabapentin at doses above 900 mg per day, where sedation risk is substantially higher
• Women with a history of syncope, orthostatic hypotension, or presyncope
• Women taking additional CNS depressants (benzodiazepines, opioids, sleep aids, muscle relaxants) alongside gabapentin, creating a triple-sedation scenario
• Women who live alone and would have no one to monitor them after the first Vyleesi use
• Anyone who has experienced significant nausea, dizziness, or flushing with prior Vyleesi doses, suggesting CNS sensitivity to the drug

Life-Stage Considerations

Trying to conceive. Stop bremelanotide at least one month before attempting pregnancy. Gabapentin's pregnancy risk should be discussed with your OB-GYN or maternal-fetal medicine specialist before conception.

Perimenopause. Bremelanotide is not approved for postmenopausal or perimenopausal women. If you are using gabapentin for perimenopausal symptoms and experiencing low desire, the appropriate next step is a conversation about hormone therapy or other evidence-based options for sexual dysfunction in this life stage, not off-label Vyleesi use.

Postpartum. Neither drug has a clean safety profile in lactation. Women with HSDD postpartum should prioritize non-pharmacologic approaches and discuss pharmacologic options after weaning.

What to Tell Your Clinician

Clear communication prevents interaction-related harm. When you see your prescribing clinician, bring the following:

• The exact dose and timing of your gabapentin (for example, "300 mg three times daily, last dose around 9 PM")
• A list of every other CNS-active drug or supplement you take, including alcohol use patterns, antihistamines, and melatonin
• Your blood pressure baseline
• Whether you have experienced dizziness or sedation from gabapentin alone
• Your contraception method, since Vyleesi affects oral contraceptive timing

Asking specifically: "Are there any timing adjustments I should make on days I use Vyleesi?" is a direct, productive question that gives your clinician actionable information to work with.

Clinician Rachel Goldberg, MD, WomanRx editorial board reviewer, notes: "In my practice, the women most at risk from this combination are those who take gabapentin at night for sleep or pain, don't report it as a 'medication' on intake forms because they think of it as routine, and then experience unexpected dizziness after their first Vyleesi dose. The interaction is manageable, but only if both prescribers know about both drugs."

The RECONNECT trials, the key phase 3 studies supporting bremelanotide's FDA approval, enrolled 1,267 premenopausal women and demonstrated a statistically significant improvement in satisfying sexual events and desire scores versus placebo. Those trials excluded women on CNS-depressant medications in most cases, meaning the safety data you are relying on when you use Vyleesi was generated in a cleaner pharmacological environment than many real-world patients occupy. This evidence gap is meaningful. The combination has not been studied in a controlled trial, and clinical guidance is based on mechanistic reasoning and pharmacovigilance data, not a dedicated interaction study in women.